Molecular neuroimaging in Alzheimer's disease

Abstract

Considerable data exist to support the use of positron emission tomography (PET) and single photon emission computed tomography (SPECT) scanning as biomarkers for Alzheimer's disease (AD). The techniques are reasonably sensitive and specific in differentiating AD from normal aging, and recent studies with pathological confirmation show good sensitivity and specificity in differentiating AD from other dementias. These techniques also can detect abnormalities in groups of asymptomatic and presymptomatic individuals and may be able to predict decline to dementia. However, there are a number of existing questions related to the use of these techniques in samples that are fully representative of the spectrum of patients with dementia. For example, it is unclear how well PET and SPECT perform in comparison to a clinical diagnosis obtained in the same patient group, when autopsy is used as a gold standard. It will also be important to know what PET and SPECT add to the certainty of diagnosis in addition to the standard clinical diagnosis. Despite these unanswered questions, PET and SPECT may have application as biomarkers for AD in a number of clinical and research settings, especially in academic centers, where most of the existing studies have been done.

FIG. 1.

FDG-PET scans in normal aging, AD, and FTD. Glucose metabolism is presented on a heat scale, with brighter colors reflecting greater glucose utilization. Glucose metabolism is reduced in posterior cortical regions (temporal and parietal lobes) in patients with AD, in contrast to frontal and anterior temporal lobe reductions in FTD.